MarketCap
Facebook
X
TelegramAnnual report 2024
added 04-18-2026
Grifols, S.A. Cash and Cash Equivalents 2011-2026 | GRFS
Annual Cash and Cash Equivalents Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 980 M | 530 M | 549 M | 2.68 B | 580 M | 742 M | 1.03 B | 887 M | 895 M | 1.14 B | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.68 B | 530 M | 1 B |
Quarterly Cash and Cash Equivalents Grifols, S.A.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 655 M | - | - | - | 580 M | - | - | - | 742 M | - | - | - | 1.03 B | - | - | - | 887 M | - | - | - | 895 M | - | - | - | 1.14 B | - | - | - | 1.08 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.14 B | 580 M | 877 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
Esperion Therapeutics
ESPR
|
168 M | $ 3.13 | 0.39 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
482 M | $ 45.86 | 3.23 % | $ 12.5 B | USA |
 |
Fortress Biotech
FBIO
|
79.4 M | $ 2.51 | 2.03 % | $ 70 M | USA |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
Galapagos NV
GLPG
|
87.9 M | $ 28.95 | 1.97 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
3.55 B | $ 27.7 | 0.59 % | $ 17.1 B |  Danmark |
 |
Genprex
GNPX
|
7.83 M | $ 0.9 | 1.28 % | $ 839 K | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 94.84 | -0.69 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
16 M | $ 2.44 | 24.11 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
22.1 M | $ 0.81 | 2.15 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
372 M | $ 76.26 | 1.34 % | $ 12.2 B | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | USA |
 |
Kamada Ltd.
KMDA
|
75.5 M | $ 8.25 | 0.49 % | $ 260 M |  Israel |
 |
INmune Bio
INMB
|
24.8 M | $ 1.55 | 0.65 % | $ 38.4 M | USA |
 |
Kymera Therapeutics
KYMR
|
357 M | $ 85.73 | 3.65 % | $ 7.24 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
7.36 M | $ 12.98 | -3.49 % | $ 1.72 B | Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
320 M | $ 22.93 | 2.6 % | $ 3.8 B | USA |
 |
Liquidia Corporation
LQDA
|
191 M | $ 42.33 | 5.48 % | $ 3.64 B | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 3.55 | 1.43 % | $ 5.84 M | Israel |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
Mirum Pharmaceuticals
MIRM
|
297 M | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
74.9 M | $ 4.01 | 40.03 % | $ 1.23 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 23.48 | 0.26 % | $ 2.99 B | USA |
 |
Nanobiotix S.A.
NBTX
|
52.8 M | $ 41.5 | 19.36 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |